We have analyzed RNA-Seq data obtained from the CD34+ cells from eight MDS cases harboring SF3B1 mutations (SF3B1-mutant, all with >15% RS), four MDS patients without splicing factor gene mutations (wild type) and five healthy individuals (control)20 using rMATS, a bioinformatics pipeline designed to detect alternative (including cryptic) splicing events involving two isoforms from an alternatively spliced region.32 These events are categorized as alternative 3′ splice site (A3SS) usage, alternative 5′ splice site (A5SS) usage, exon skipping, mutually exclusive exons or retained introns. This evidence concerns the gene CD34 and myelodysplastic syndrome.